The Clinical Implementation of CYP2C19 Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry.
Jaouad AzzahhafiWout W A van den BroekDean R P P Chan Pin YinAnkie M HarmszeRon H N van SchaikJurriën M Ten BergPublished in: Journal of cardiovascular pharmacology and therapeutics (2023)
CYP2C19 genotype-guided-de-escalation in an all-comers ACS population is feasible. POC genotyping leads to shorter turnaround times and quicker de-escalation. Time to de-escalation from ticagrelor to clopidogrel in noncarriers was short, with high physician adherence to genotype results.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- open label
- antiplatelet therapy
- primary care
- genome wide
- high throughput
- emergency department
- healthcare
- st segment elevation myocardial infarction
- single molecule
- clinical trial
- dna methylation
- metabolic syndrome
- quality improvement
- skeletal muscle
- coronary artery disease
- glycemic control